Recombinant human C1-esterase inhibitor for the prevention of acute hereditary angioedema attacks: a case report

AbstractBackground: Prophylaxis may be considered for frequent acute attacks of hereditary angioedema (HAE); moreover, prophylaxis efficacy may impact direct costs associated with medical utilization/medication.Objectives: To present data on the efficacy and cost savings of investigational prophylactic treatment with recombinant human C1-esterase inhibitor (rhC1-INH).Methods: Retrospective chart review of patient with HAE.Results: A white female aged 52 years who had experienced HAE attack symptoms since age 16 years was diagnosed at age 37 years with type 1 HAE. She received danazol 400 mg/d; attempts to lower her dose were unsuccessful. She continued to experience daily extremity swelling and had abdominal edema with intense pain severe enough to warrant hospitalization every 2–3 months. In 2012, she began prophylaxis with plasma-derived C1-INH (pdC1-INH) 1000 IU 3 times weekly (TIW) at a weekly cost of ∼$16,500. During a 12-month period (September 2013 to September 2014), authors documented 13 emergenc...